



PCT/CH 2004/000363

SCHWEIZERISCHE EIDGENOSSENSCHAFT
CONFÉDÉRATION SUISSE
SWISS CONFEDERATION

REC'D 21 JUN 2004

WIPO PCT

Bescheinigung

Die beiliegenden Akten stimmen überein mit den ursprünglichen Unterlagen der auf den nächsten Seiten bezeichneten, beim unterzeichneten Amt als Anmeldeamt im Sinne von Art. 10 des Vertrages über die internationale Zusammenarbeit auf dem Gebiet des Patentwesens (PCT) eingegangenen Patentanmeldung.

Attestation

Les documents ci-joints sont conformes aux pièces originales relative à la demande de brevet spécifiée aux pages suivantes, déposées auprès de l'Office soussigné, en tant qu'Office récepteur au sens de l'article 10 du Traité de coopération en matière de brevets (PCT).

Confirmation

It is hereby confirmed that the attached documents are corresponding with the original pages of the international application, as identified on the following pages, filed under Article 10 of the Patent Cooperation Treaty (PCT) at the receiving office named below.

Berne, le 16 juin 2004


**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

Eidgenössisches Institut für Geistiges Eigentum
Institut Fédéral de la Propriété Intellectuelle
Swiss Federal Intellectual Property Institute

Patentverfahren
Administration des brevets
Patent Administration

Rolf Hofstetter





Copie pour l'office récepteur

1/4

PCT REQUEST

271-1.B.WO-P

Original (for SUBMISSION) - printed on 18.06.2003 10:58:20 AM

0	For receiving Office use only	
0-1	International Application No.	PCT/CH 03 / 00398
0-2	International Filing Date	19. Juni 2003 (19.06.03)
0-3	Name of receiving Office and "PCT International Application"	RO/CH - Demande internationale PCT
0-4	Form - PCT/RO/101 PCT Request	
0-4-1	Prepared using	PCT-EASY Version 2.92 (updated 01.04.2003)
0-5	Petition The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty	
0-6	Receiving Office (specified by the applicant)	Swiss Federal Intellectual Property Institute (RO/CH)
0-7	Applicant's or agent's file reference	271-1.B.WO-P
I	Title of invention	PROTEIN PRODUCTION SYSTEM
II	Applicant	
II-1	This person is:	applicant and inventor
II-2	Applicant for	all designated States
II-4	Name (LAST, First)	BROMLEY, Peter
II-5	Address:	18, rue Cavour CH-1203 Genève Switzerland
II-6	State of nationality	GB
II-7	State of residence	CH
II-8	Telephone No.	+41.79.319.10.65
II-10	e-mail	peter.bromley@tge-corp.com
IV-1	Agent or common representative; or address for correspondence The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as:	agent
IV-1-1	Name (LAST, First)	ROLAND, André
IV-1-2	Address:	Avenue Tissot 15 cp 1255 CH-1001 Lausanne Switzerland
IV-1-3	Telephone No.	+41-21.321.44.10
IV-1-4	Facsimile No.	+41-21.321.44.12
IV-1-5	e-mail	contact@andreroland.com



PCT REQUEST

271-1.B.WO-P


Original (for SUBMISSION) - printed on 18.06.2003 10:58:20 AM

V	Designation of States	
V-1	Regional Patent (other kinds of protection or treatment, if any, are specified between parentheses after the designation(s) concerned)	<p>AP: GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW and any other State which is a Contracting State of the Harare Protocol and of the PCT</p> <p>EA: AM AZ BY KG KZ MD RU TJ TM and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT</p> <p>EP: AT BE BG CH&LI CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR and any other State which is a Contracting State of the European Patent Convention and of the PCT</p> <p>OA: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG and any other State which is a member State of OAPI and a Contracting State of the PCT</p>
V-2	National Patent (other kinds of protection or treatment, if any, are specified between parentheses after the designation(s) concerned)	<p>AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH&LI CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW</p>
V-5	Precautionary Designation Statement In addition to the designations made under Items V-1, V-2 and V-3, the applicant also makes under Rule 4.9(b) all designations which would be permitted under the PCT except any designation(s) of the State(s) indicated under Item V-6 below. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit.	
V-6	Exclusion(s) from precautionary designations	NONE
VI	Priority claim	NONE
VII-1	International Searching Authority Chosen	European Patent Office (EPO) (ISA/EP)



PCT REQUEST

Original (for SUBMISSION) - printed on 18.06.2003 10:58:20 AM

VIII	Declarations	Number of declarations	
VIII-1	Declaration as to the identity of the Inventor	-	
VIII-2	Declaration as to the applicant's entitlement, as at the international filing date, to apply for and be granted a patent	-	
VIII-3	Declaration as to the applicant's entitlement, as at the international filing date, to claim the priority of the earlier application	-	
VIII-4	Declaration of inventorship (only for the purposes of the designation of the United States of America)	-	
VIII-5	Declaration as to non-prejudicial disclosures or exceptions to lack of novelty	-	
IX	Check list	number of sheets	electronic file(s) attached
IX-1	Request (including declaration sheets)	4	-
IX-2	Description	17	-
IX-3	Claims	1	-
IX-4	Abstract	1	EZABST00.TXT
IX-5	Drawings	0	-
IX-7	TOTAL	23	
	Accompanying Items	paper document(s) attached	electronic file(s) attached
IX-8	Fee calculation sheet	✓	-
IX-17	PCT-EASY diskette	-	Diskette
IX-19	Figure of the drawings which should accompany the abstract		
IX-20	Language of filing of the international application	English	
X-1	Signature of applicant, agent or common representative		
X-1-1	Name (LAST, First)	ROLAND, André	

FOR RECEIVING OFFICE USE ONLY

10-1	Date of actual receipt of the purported international application	19. Juni 2003 (19. 06. 03)
10-2	Drawings:	
10-2-1	Received	
10-2-2	Not received	
10-3	Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application	
10-4	Date of timely receipt of the required corrections under PCT Article 11(2)	
10-5	International Searching Authority	ISA/EP
10-6	Transmittal of search copy delayed until search fee is paid	X



PCT REQUEST

Original (for SUBMISSION) - printed on 18.06.2003 10:58:20 AM

FOR INTERNATIONAL BUREAU USE ONLY

11-1	Date of receipt of the record copy by the International Bureau	
------	---	--



PROTEIN PRODUCTION SYSTEM

The present invention relates to an Optimized Protein Production System using a Stable and Competent Human Hepatocyte Cell Line

BACKGROUND

Therapeutic proteins have been known in the scientific and medical communities since the early twentieth century, but the small amounts harvestable from tissues and urine made therapeutic replacement difficult if not impossible. In the 1980s, advances in genomic technology have directly facilitated the identification, isolation, and characterization of genes responsible for the production of a great number of potential therapeutic proteins ('biotherapeutics').

Recombinant DNA technology allows the large-scale manufacture and production of many therapeutic proteins. This approach may use either a prokaryotic or eukaryotic source of cells for propagation. The function and efficacy of any protein - and, by proxy, a therapeutic protein, depends mainly on the gene sequence; however, several post-translational modifications to the protein may also play a crucial role in the ability of the protein to function with maximum efficacy.

Post-translational modifications (PTMs) change the property of the side groups of the amino acids - the building blocks of proteins - such that they alter protein function. Collectively, these post-translational modifications contribute significantly to the final structure and function of the protein. Therefore, when therapeutic proteins are made for use in humans, it is thought to be important to have the human pattern of post-translational accompaniments on the protein.

Industry example: The original production of EPO in prokaryotic cells failed because the post-translational patterns imparted by the bacterial host-cell to its transfected human gene product were neither correct nor sufficient to confer appropriate levels of clinical efficacy to the drug. Therefore, the decision to produce EPO in mammalian - but not human - cells was an important point in the evolution of the drug.



DOCUMENTED DIFFERENCES BETWEEN NATIVE VS RECOMBINANT THERAPEUTIC PROTEINS

Reports on the importance of correct PTMs with respect to biological activity/therapeutic efficacy of biotherapeutics abound, particularly in the view of the impending flood of new biotherapeutic molecules in clinical development. Below are some examples of reported studies:

The glycosylation (a major PTM) of recombinant glycoproteins can profoundly affect their biological activities, including circulatory clearance rate, and recombinant proteins that are correctly glycosylated have significantly longer serum half lives than incorrectly glycosylated structures (Chitlaru et al., 1998)¹.

Important glossary terms:

Native protein: a protein that is routinely synthesized by a given tissue, organ, cell in the natural physiological state, in absence of any manipulation or engineering.

Recombinant protein: a gene product (protein) that is obtained after genetically engineering of a cell or organism.

Misaizu et al (1995)² found that the nature and degree of glycosylation of recombinant human erythropoietin (EPO) profoundly affected the in vivo activity. Incorrect glycosylation patterns enhanced the total body clearance rate more than three times and resulted in a much lower activity for stimulation of erythroid progenitor cells.

In many cases, there are significant differences in glycosylation between native and recombinant glycoproteins, between recombinant forms expressed in different cell lines, and between related glycoproteins from different organs. Landberg et al., (1997)³ found differences in the glycosylation of native and recombinant forms of bile-salt-stimulated lipase (BSSL) from human milk. Native BSSL contained a high amount of A2F family N-glycans whereas recombinant forms expressed in CHO or mouse fibroblast cell lines had predominantly A2 family glycans.

Jacquinet et al., (1994)⁴ studying the oligosaccharides of transferrins from chicken serum, chicken embryo serum and from the culture medium of chicken embryo hepatocytes in primary culture found each had distinct glycosylation patterns.

¹ Chitlaru T, Kronman C, Zevel M, Kam M, Harel A, Ordentlich A, Velan B, Shafferman A (1998). Modulation of circulatory residence of recombinant acetylcholinesterase through biochemical or genetic manipulation of sialylation levels. *Biochem J* 1998 336:647-658.

² Misaizu T, Matsuki S, Strickland TW, Takeuchi M, Kobata A, Takasaki S (1995). Role of antennary structure of N-linked sugar chains in renal handling of recombinant human erythropoietin. *Blood* 86:4097-4104.

³ Landberg E, Pahlsson P, Krotkiewski H, Stromqvist M, Hansson L, Lundblad A (1997). Glycosylation of bile-salt-stimulated lipase from human milk: comparison of native and recombinant forms. *Arch Biochem Biophys* 344:94-102.

⁴ Jacquinet PM, Leger D, Wieruszkeski JM, Coddeville B, Montreuil J, Spik G (1994). Change in glycosylation of chicken transferrin glycans biosynthesized during embryogenesis and primary culture of embryo hepatocytes. *Glycobiology* 4:617-624.



Tanigawara et al., (1990)⁵ demonstrated that two preparations of r-tPA's (recombinant tissue plasminogen activators) with different carbohydrate structures showed different pharmacokinetics, strongly suggesting that the carbohydrate structure can affect the biological activity, hence the therapeutic efficiency, of t-PA.

WHY NATIVE PROTEINS ?

Recombinant proteins that lack correct human post-translational modifications can elicit neutralizing antibodies, resulting in reduced efficacy. Moreover, recombinantly-produced proteins are often cleared from circulation quickly, requiring frequent injections or pegylation to extend the half-life. "Pegylated" proteins are costly to produce and may lose some of their bioactivity, requiring higher dosage for the same efficacy.

Conversely, native proteins from human tissues are fully human glycosylated, providing products with clear activity/efficacy/safety advantages over current therapies:

Better and broader efficacy due to the presence of naturally-occurring glycan structures and subtypes on the final protein product as well as other post-translational modifications, more closely matching human therapeutic requirements;

Potentially fewer side effects due to lower dosage;

Longer half life in circulation and little allergic response due to proper PTMs;

Lower manufacturing cost due to the extraction of multiple proteins from a single cell source and manufacturing process;

Lower regulatory barrier due to use of a single immortalized human cell line and single manufacturing process;

Less frequent injections due to longer half-life of glycosylated proteins compared to non-glycosylated recombinant proteins produced in bacteria.

Industry example: Glycogen storage disease type II (GSDII) is an autosomal recessive disorder caused by the deficiency of the protein GAA (acid alpha-glucosidase), a glycogen-degrading lysosomal enzyme.

This deficiency results in generalized deposition of lysosomal glycogen in almost all tissues of the body and can ultimately lead to cardiac failure before the age of two years (hence GSDII is a life-threatening condition).

⁵ Tanigawara Y, Hori R, Okumura K, Tsuji J, Shimizu N, Noma S, Suzuki J, Livingston DJ, Richards SM, Keyes LD, et al. (1990). Pharmacokinetics in chimpanzees of recombinant human tissue-type plasminogen activator produced in mouse C127 and Chinese hamster ovary cells. Chem Pharm Bull (Tokyo) 1990 Feb;38(2):517-22



Current treatment for the disease includes repairing the deficiency by injecting recombinant protein into the patient, made from either cultured Chinese Hamster Ovary (CHO) cells or secreted in the milk from rabbits that bear the transgene for the protein under a milk-specific promoter.

Both recombinant proteins produced are extremely inefficient in their uptake into and function in targeted tissues.

The NIH (US-National Institute of Health) announces a new technology that relates to the use of hepatocytes whether in culture or in vivo for the production of native human GAA.

The NIH approach is to use human hepatocytes to produce appropriate post-translational modification of the enzyme in cells by proper glycosylation, thereby producing a superior enzyme capable of being easily taken up and localized intracellularly in the target tissue. Once there, the enzyme digests glycogen present in lysosomes.

PROTEINS NATURALLY PRODUCED BY THE LIVER

The liver is one of the most promising organs/tissues to provide producer cells with a large spectrum potential for delivering native proteins with therapeutic interest, either as direct biological drugs or as validated drug targets for small drug molecule development. Indeed, this organ synthesizes a host of important proteins, including enzymes, hormones, clotting factors, and immune factors. Several proteins synthesized by the liver are necessary for proper blood functioning; these include binding proteins and albumin, which helps maintain proper blood volume. Clotting factors produced by the liver include fibrinogen, prothrombin (Factor II), Factors VII, VIII, IX, X and von Willebrand Factor. Acute phase proteins (APP) are another set of plasma proteins synthesized by the liver in response to tissue damage and inflammation associated with traumatic and/or infectious disease. Transferrin (Tf), alpha-2-macroglobulin (a2M), hemopexin are just some important acute proteins.

(Please refer to the APPENDIX for a comprehensive list of proteins produced by hepatocytes).

[MF notes: in case this issue is considered a valuable avenue to explore, all potential disease/therapeutic targets for each protein from the appendix list can be supplied]

LIMITATIONS OF THE NATIVE LIVER PROTEINS APPROACH

Primary hepatocytes do not proliferate, thus production of proteins from this type of cells requires a steady supply of new cellular preparations from human liver biopsies. This would represent a clumsy and expensive approach with many associated problems (QA, batch-to-batch variability, almost no standardization, regulatory hassle). This issue has been solved through TGE-Corp's in-licensing strategy (Multicell Technologies' unique immortalized and standardized fully competent human hepatocytes).



The remaining limit for producing native hepatic proteins for therapeutic or other uses is obviously determined by the set of proteins available at a decent yield from hepatic cells in culture. The APPENDIX section lists all major proteins that could potentially be manufactured under the label of 'Native Proteins'.

Any other therapeutic protein candidate will have to be produced using genetic engineering strategies. However, even in this case, the human nature/origin of these cellular substrates (MCT's hepatic cell lines) should guarantee the best post-translational modification process currently available, thus leading to recombinant end-products with clear competitive advantages, including a favourable regulatory outlook.



APPENDIX 1

BASIS FOR THE CONSTRUCTION OF HIGH EFFICIENCY, INDUCIBLE PROMOTER - GENE CONSTRUCTS, EXPRESSING THERAPEUTIC PROTEINS.

An expression vector will be constructed which allows for the selection of stable transfectants by selection for the zeocin antibiotic (Cayla) in both prokaryotic and eukaryotic cells. The Zeocin resistance gene will be obtained as a restriction digest fragment from the pZeoSV plasmid (Invitrogen) and will be ligated to a fragment containing a bacterial origin of replication obtained by PCR amplification from pUC19 (New England Biolabs). This ligation mixture will then be used to transform competent *E. coli* cells and the presence of the desired recombinant plasmid (pUC-Zeo) will be selected for on Zeocin-containing bacterial plates. A synthetic poly(A) sequence will be obtained as a restriction fragment from a digest of pGL3-Basic (Promega) and will be ligated into pUC-Zeo upstream of the HSP70B promoter and the desired recombinant (pUC-ZeoA) will be selected for Zeocin resistance. The HSP70B driven expression cassette (Hi-Hot) will be obtained as a restriction fragment from the PCR amplification of pHi&Hot-MCS (V3) (David Harris, University of Arizona) from which an XhoI fragment in the multiple cloning region has been deleted. The Hi-Hot expression cassette will be ligated into pUC-ZeoA downstream of the synthetic poly(A) sequence and the desired recombinant (pHiHot-Zeo) will be selected for Zeocin resistance. Genes to be expressed under the control of the Hi-Hot system can be inserted into the unique XhoI and XbaI sites derived from the multiple cloning sequence of pHi&Hot-MCS. The Hi-Hot plasmid constructs are derived from those in Tsang et al., *Biotechniques*, 20:51-52, 1996 and Tsang et al., *Biotechniques*, 22:68.

In a comparison of expression systems in transient transfection experiments using the Lewis Lung Carcinoma cell line expressing Interleukin-2, the following results were obtained:

Hsp70B promoter – 468 pg/ml of interleukin-2

CMV promoter – 573 pg/ml of interleukin-2

Hi-Hot promoter – 18,409 pg/ml of interleukin-2

THE HI-HOT PROMOTER WAS 39.3 TIMES STRONGER THAN THE HSP70B PROMOTER AND 32.1 TIMES STRONGER THAN THE CMV PROMOTER

.

.



.

.

.

..

.

.

...

.

..

.

.

.

...

..

APPENDIX 2**SHORTLIST OF NATIVE HEPATIC PROTEINS**

Abbreviated Protein Name(s)

202	Ifi 202
3alpha HSD/DD	3alpha hydroxysteroid dihydrodiol dehydrogenase, AKR1C9, aldo-keto reductase 1C9
A2-Mag	alpha2-macroglobulin
A2UG	alpha-2u globulin clone RAO 01
A2UG207n	alpha-2u globulin 207
AAT	alpha1-antitrypsin
ACC	acetyl-CoA carboxylase
ACE	angiotensin converting enzyme , DCP, DCP1, dipeptidyl carboxypeptidase I, angiotensin I converting enzyme, peptidyl-dipeptidase A 1, CD143, dipeptidyl peptidase, Kininase II, ACE1
ACO	acyl CoA oxidase
ACS	acyl-coenzyme A synthetase , long-chain-acyl-CoA synthetase
ADB	aldolase B
ADH1	alcohol dehydrogenase 1, class I, alcohol dehydrogenase alpha subunit
ADH2	alcohol dehydrogenase 2, class I
ADH3	alcohol dehydrogenase 3, class I
AFP	alpha-fetoprotein
aG	alpha1-globin
AGG	Agamma globin, hemoglobin gamma chain
AGP	alpha-1-acid glycoprotein
ALAD	delta-aminolevulinate dehydratase, porphobilinogen synthase
ALB	albumin
ALDH-3	Class 3 aldehyde dehydrogenase, fatty aldehyde dehydrogenase, aldehyde dehydrogenase microsomal
alpha113	alpha1-inhibitor III
alpha2MR/LRP	alpha2-macroglobulin receptor/lipoprotein receptor-related protein
AML1	acute myeloid leukemia 1, CBFA2, core-binding factor, runt domain, alpha subunit 2
ANG	angiotensinogen



Abbreviated Protein Name(s)

AOX	acyl CoA oxidase , acyl-CoA: oxygen 2-oxidoreductase
APO(A)	apolipoprotein(a)
apoAI	apolipoprotein AI
ApoA-I	apolipoprotein A-I
apoAII	apolipoprotein AII
ApoA-IV	apolipoprotein A-IV
apoB	apolipoprotein B
apoC-III	apolipoprotein C-III
ApoD	apolipoprotein D
apoE	apolipoprotein E
apoVLDLII	very low density lipoprotein II , apovitellenin I
ARG	arginase
AT1a-R	angiotensin II type 1A receptor , angiotensin receptor (AT1)
ATPIA1	Na,K-ATPase alpha 1 subunit , NAKA alpha 1
beta2-AR	beta2-adrenergic receptor
beta-IFN	virus induced interferon-beta , IFN beta
Bf	complement factor B
BFIBR	fibrinogen B-beta subunit
BGP	biliary glycoprotein, C-CAM-1, cell CAM-1, BGP-1, BGPI, antigen CD66, CD66A antigen
C/EBPalpha	CCAAT/enhancer binding protein alpha
C3	complement C3
C4BP	C4b-binding protein
cAspAT	cytosolic aspartate aminotransferase
catalase	catalase, CAT, CAS1
Cdc 7	Cell division cycle 7
CEBPA	CCAAT/enhancer binding protein alpha
CETP	cholesteryl ester transfer protein
COL1A1	collagen, type I, alpha 1
CRBP II	cellular retinol-binding protein II
CRP	C-reactive protein
CSP 1	carbamoylphosphate synthetase 1
Cyp11A	cytochrome P450 cholesterol side chain cleavage , P450scc

.

.



Abbreviated Protein Name(s)

Cyp17	cytochrome P-450 17alpha hydroxylase/C17-20 lyase , P450c17
Cyp19	aromatase , cytochrome P450XIXA1 , estrogen synthetase , P450arom
CYP1A1	cytochrome P450 family I A 1, P1-450, cytochrome P-450IA1
Cyp21A1	cytochrome P450 steroid 21-hydroxylase , P450C21 , CypXXIA1 , 21-OHase
CYP27	Cytochrome P-450c27
CYP2B2	cytochrome P450IIB2
CYP2C12	Cytochrome P-450 family 2 C 12
CYP7	cholesterol 7-alpha-hydroxylase , cholesterol 7-alpha-monooxygenase, cytochrome P450 VII
DRA	MHC class II HLA-DRA
ei24	etoposide induced protein 2.4, PIG8
EKLF	erythroid Kruppel-like factor
Epo	erythropoietin
F10	coagulation factor X, coagulation factor 10, stuart factor, f10
F7	factor VII, vitamin K-dependent coagulation protein
F8	coagulation factor VIII, F8C, procoagulant component, antihemophilic factor, AHF
F9	coagulation factor IX , Factor IX, Factor 9, christmas factor, FLX, f9
FAS	fatty acid synthase
FASL receptor	Fas ligand receptor, Fas antigen, Fas death receptor, APO-1 antigen, CD95 antigen, TNFRSF6, APT1, FAS
FCH	ferrochelataase, protoheme ferro-lyase, heme synthetase
FGG	FIBRINOGEN GAMMA, FIBG
fibrinogen gamma	gamma-fibrinogen subnit
FPPS	farnesyl diphosphate synthase , geranyl-diphosphate: isopentenyl-diphosphate geranyltranstransferase
FTH	ferritin, heavy chain
G6Pase	glucose-6-phosphatase
GADI	glutamic acid decarboxylase 2 , 67kDa glutamate decarboxylase , GAD67
GATA-1	GATA-1
Gbp-1	guanylate-binding protein-1, mGBP-1, mag-1, macrophage activation -1
Gbp-2	guanylate-binding protein-2, mGBP-2, macrophage activator
GGG	Ggamma-globin



Abbreviated Protein Name(s)

GK	glucokinase, hexokinase D, hexokinase type IV, HK4, ATP:D-hexose 6-phosphotransferase
GLOB-A	alpha1-globin, hemoglobin alpha1 chain
GLOB-B	beta-globin, hemoglobin beta chain
GLOB-BM	betaM-globin, hemoglobin beta major chain
GLOB-Z	zeta2-globin, hemoglobin z2 chain
GPA	glycophorin A
GPAT	mitochondrial glycerol-3-phosphate acyltransferase
GPC	glycophorin C
gpD	glycoprotein D, major subunit of Duffy blood group
GSHPx	cytosolic glutathione peroxidase, cellular glutathione peroxidase, GPX1
gstA2	Glutathione S-transferase A2
GST-P	glutathione transferase P, placental glutathione transferase, glutathione S-alkyl transferase
GSTYA	glutathione S-transferase Ya subunit
GST-Ya	glutathione S-transferase Ya subunit
H-2Dd	MHC class I H-2Dd
H-2Kb	MHC class I H-2Kb
H-2Kk	MHC class I H-2Kk
H-2Ld	MHC class I H-2Ld
HCEH	hepatic neutral cholesterol ester hydrolase, neutral cholesterol ester hydrolase, hepatic cholesterol ester hydrolase
HD	hydratase-dehydrogenase, enoyl-CoA hydratase / 3-hydroxyacyl-CoA dehydrogenase, bifunctional enzyme
HG	haptoglobin
HK3	hexokinase 3, HK III
HMGCR	HMG-CoA reductase, 3-hydroxy-3-methylglutaryl-coenzyme A reductase, 3-hydroxy-3-methylglutaryl-coA reductase
HMGCS	3-hydroxy-3-methylglutaryl coenzyme A synthase, hydroxymethylglutaryl-CoA synthase, cytoplasmic, HMG-CoA synthase
HMGR	3-hydroxy-3-methylglutaryl coenzyme A reductase
HNF-1	hepatocyte nuclear factor-1, LFB1, LFB1/HNF1, HNF-1alpha
HNF-1beta	hepatocyte nuclear factor-1 beta, vHNF-1
Hnf-3alpha	hepatocyte nuclear factor 3alpha
HNF3beta	hepatocyte nuclear factor 3 beta

.

.



Abbreviated Protein Name(s)

HNF3gamma	hepatocyte nuclear factor 3 gamma
HNF-4	hepatocyte nuclear factor 4
HO-1	heme oxygenase 1, hsp32
HPG	haptoglobin
Hpx	hemopexin
hsc70	72 kd heat shock cognate
hsc77	heat shock cognate 73, HSC72, P72, HSC70, peroxisome proliferator binding protein
HSF1	heat shock factor 1, HSTF1
HSF2	heat shock factor 2, HSTF2
HSP105	heat shock protein 105
hsp25	heat shock protein 25
hsp84	84 kDa heat shock protein, HSP90B
HSPG2	Basement membrane-specific heparan sulfate proteoglycan core protein , perlecan, HSPG, PLC
HTGL	hepatic triglyceride lipase , triacylglycerol lipase
ICAM-1	intercellular adhesion molecule-1 , major group rhinovirus receptor, HRV, CD54
IFN-alpha	interferon-alpha
IGFBP-1	insulin-like growth factor binding protein-1
IGF-II	insulin-like growth factor II
iNOS	inducible nitric oxide synthase, NOS2, hiNOS, inducible NOS, macrophage-type NOS, iNOS, NOS, type II, NOS2A, hepatocyte OS, hep-NOS
IP-10	inflammatory protein 10-kDa, Crg-2, gamma-IP10, C7, INP10, IFI10, SCYB10
IR	insulin receptor
IRF-1	interferon regulatory factor 1
Itgb5	integrin beta 5
LPL	lipoprotein lipase
MCAD	medium-chain acyl-CoA dehydrogenase, acyl-CoA dehydrogenase, medium-chain specific , 2,3-oxidoreductase , ACADM
MDR1	multidrug resistance , PGY1, P-glycoprotein
mdr1b	multidrug resistance 1b, P-glycoprotein , mdr1
ME	malic enzyme , malate oxidoreductase
MHMGCS	mitochondrial 3-hydroxy-3-methylglutaryl coenzyme A synthase , mitochondrial HMG-CoA synthase



Abbreviated Protein Name(s)

MT-I	metallothionein-I
MTP	microsomal triglyceride transfer protein
MXI1	Max Interactor 1
NFE2	nuclear factor erythroid 2, nuclear factor (erythroid-derived 2), 45kD, P45 NF-E2, leucine zipper protein NF-E2, NFE2, p45, NF-E2
NPY	neuropeptide Y
NQO1	NAD(P)H:quinone oxidoreductase, DT diaphorase, NMO1, NMOR, QR, QAO
OAS	2'-5' oligoadenylate synthetase, 2'-5' A synthetase
ODC	ornithine decarboxylase , L-ornithine carboxilase
OTC	ornithine transcarbamylase, L-ornithine carbamoyltransferase
p44	hepatitis-C-associated microtubular aggregate protein
P450c	cytochrome P450 family I A 1
p53	p53 tumor suppressor
PAH	Phenylalanine hydroxylase
PBGD	porphobilinogen deaminase, porphobilinogen ammonia-lyase (polymerizing), hydroxymethylbilane synthase
PCNA	proliferating cell nucleolar antigen p120
PEPCK	phosphoenolpyruvate carboxykinase cytosolic, phosphopyruvate carboxylase
PFKFB	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase , 6PF-2-K/Fru-2,6-P2ASE, PFK-2/FBPase-2, RH2K
PGK-1	phosphoglycerate kinase 1 somatic-type
pIgR	polymeric immunoglobulin receptor, polyimmunoglobulin receptor, polymeric IgA receptor
pk L	L-type pyruvate kinase
PPAR gamma	peroxisome proliferator activated receptor gamma , PPAR gamma 3, PPAR gamma 1
PRLR	prolactin receptor
Pt	prothrombin, coagulation factor II, F2
PYKM	M-type pyruvate kinase , PKM2, Pyruvate kinase, M
RAR-beta	retinoic acid receptor beta, Retinoic Acid Receptor beta 2 , RAR-beta
RBTN2	Rhombotin 2, T-cell translocation 2, TTG-2
S14	S14 product
SAA	serum amyloid A
SAA1	serum amyloid A1



Abbreviated Protein Name(s)

SAA3	serum amyloid A3
SAAg9	serum amyloid Ag9
sgk	Serin/Threonine protein kinase
SIRP	signal-regulatory protein
SOD1	Cu/Zn superoxide dismutase
Spi 2.1	serine protease inhibitor 2.1, serpin
Spi 2.3	serine protease inhibitor 2.3, SPI, serpin, contrapsin-like protease inhibitor precursor, kallikrein-binding protein, GHR-p63
SPTB	beta-spectrin, SPTB1
SREBP-2	sterol regulatory element-binding protein-2
SS	squalene synthase, farnesyl-diphosphate: farnesyl-diphosphate farnesyltransferase
Stat6	Interleukin-4-induced transcription factor Stat6, IL-4 Stat
TALI,	SCL, TCL5
TAT	tyrosine aminotransferase
TF	transferrin
THPO	thrombopoietin, c-Mpl ligand, megakaryocyte colony stimulating factor, megakaryocyte growth and development factor
TO	tryptophan oxygenase
TOP3	DNA topoisomerase III alpha, TOP3A, hTOP3
TTR	transthyretin, prealbumin
VIT-A2	vitellogenin A2
VIT-B1	vitellogenin B1
VIT-II	vitellogenin II
vWF	von Willebrand factor
XOR	xanthine oxidoreductase, XDH, XDHA
zg	zeta-globin, hemoglobin z-chain

.

.



APPENDIX 3

EXISTING HUMAN CELL LINE PRODUCTION SYSTEMS TODAY

The initial success of biotechnology has been driven some 30 years ago, by the ability to transfer DNA sequences into living cells and make them produce therapeutic proteins/peptides on a large scale. The production of recombinant insulin was the first example of such a process, achieved in the 1970ies by introducing the insulin gene into bacteria, the simplest cell type available. These 'engineered bacteria' then produced insulin which to date is still successfully used to combat diabetes.

As the biotechnology industry became interested in the production of more complex protein drugs, more sophisticated producer cell types were required as a production platform. In the early 80ies, the large-scale manufacturing of therapeutic proteins in mammalian cells represented a major breakthrough. To date, animal cells, such as rodent cell lines, and in particular the Chinese Hamster Ovary cell line (CHO), represent the most important platform for the production of biopharmaceuticals, including some blockbuster biotech drugs.

However, in recent past clinical trials, in particular with recombinant murine antibodies, it rapidly became clear that nonhuman antibodies have the potential to elicit an immune response, thus blocking the efficacy of the treatment. These observations underscored the now recognized importance of correct 'human-type' post-translational modifications of complex protein products.

PER.C6™

The company Introgen b.v. (Leiden, NL), now Crucell, took the bioproduction process one step further from rodent to a human production platform. PER.C6™ is an expression platform that consists of a human cell line that can produce biopharmaceuticals for human therapeutic use. The PER.C6 cell line was generated from human retina-derived primary cells, which were immortalized by insertion of the adenovirus E1 gene. The cell line is derived from a single source of healthy human cells in a controlled and fully documented manner. The company has immortalized the cell so that it can replicate itself indefinitely, unlike normal human cells, a prerequisite feature essential to the production of recombinant biopharmaceutical products in sufficient quantities for commercial distribution.

Currently, Crucell promotes its PER.C6 production platform for the :

Production of monoclonal antibodies through rDNA technologies;



Production of various therapeutic proteins other than mAb's;

Vaccine production

Adenoviral vector production for gene therapy applications

Functional genomics

WHY PER.C6™

Crucell, the PER.C6 owner company, claims its platform to represent today's industry standard for applications such as 1 – 4 above. The main reason to this stems from the following assertion: "Crucell's Technology Maintains 'Human' Glycosylation Patterns."

Major advantages of using PER.C6 cells for biopharmaceutical production:

Post-translational modifications (in particular Glycosylation): Optimal recombinant therapeutic protein products, in terms of half-life, biological activity and immunocompatibility contain human glycan structures (i.e. glycosylation patterns). Mammalian cells like CHO (the biotech 'workhorse') or other established non-human animal cell lines add non-human glycan structures to recombinant proteins or antibodies. PER.C6 cells perform human glycosylation patterns, resulting in higher biological activity and longer half-life.

Regulatory issues: As PER.C6 has been developed as a manufacturing platform for biopharmaceuticals, extensive documentation concerning the generation and characterization of the cell line has been assembled from the start. This documentation has been deposited as a biologics master file (BMF) with the FDA. PER.C6 has been approved for the generation of recombinant adenovirus for gene therapy trials, and has been accepted for Phase I/II clinical trials of an HIV vaccine being administered to both healthy and immunocompromised individuals.

Production yields – monoclonals: Currently used expression platforms for the production of monoclonal antibodies are CHO and NS/O cells, with average expression yields amounting to approximately 0.5 g/l in final production processes. PER.C6 produce similar levels of antibodies in a non-optimized system and is expected to produce significantly more in optimized fed batch culture systems.

Intellectual Property: Crucell, Leiden, NL, wholly owns the technology and know-how associated with PER.C6, which translates into a transparent patent situation, which is far from being the case for all other production platforms for biopharmaceuticals.

Flexibility of use: The cells grow readily as adherent or suspension cultures, in serum-free and animal-component-free culture systems and can be easily transferred from one medium or growth condition to another.



Scalability: The presence of the adenovirus E1 gene inhibits apoptosis of PER.C6 cells, resulting in high viabilities when grown in batch production cultures. PER.C6 cells are easily scalable – the cells are currently grown in 2,500 L reactors and further upscaling is in progress.

Stability: Transfection of PER.C6 cells with expression plasmids is efficient, as is subsequent generation of stable sub-clones. Importantly, high expression levels of recombinant proteins are observed in the absence of gene amplification, giving a considerable time advantage over the use of cell lines that require amplification for efficient protein expression.

In a May 2002 hearing⁶, the FDA considered the potential risks in using two novel cell substrates, i.e. HEK293 cells and PER.C6 cells. These cell lines were developed by transforming human embryonic kidney cells (293) and human embryonic retinal cells (PER.C6) with the transforming early region 1 (E1) of adenovirus type 5 (Ad5). Since cell lines such as 293 and PER.C6 express the Ad5 E1 region, they are able to complement the growth of defective Ad5 vectors which have been "crippled" by deletion of E1. Defective Ad5 vectors have been engineered to express foreign genes such as those from human immunodeficiency virus (HIV), the causative agent of AIDS, and vectors of this type are thought to have significant potential for vaccine development because of their demonstrated ability to generate cell-mediated immune responses to HIV. However, a feature of regulatory importance associated with Ad5-transformed cells is their capacity to form tumors in immunodeficient animals such as nude mice.

In considering potential risks associated with the use of so-called Designer Cell Substrates – i.e., neoplastic cells derived from normal cells transformed by defined viral or cellular oncogenes or by immortalizing cellular genes (e.g., telomerase) – OVR/CBER is considering the approach outlined within the framework of a "defined-risks" assessment⁷. This framework is intended to examine, and wherever possible, to quantify the potential risk of "transmitting" the tumorigenic components of the cell substrate used for vaccine production, and determine whether that "transmission" might pose a risk, particularly an oncogenic risk, to vaccinees. Factors that could influence the risk associated with the use of Designer Cell Substrates include (a) the known mechanism of cell transformation leading to the development of tumorigenic cells; (b) residual cell substrate DNA; and (c) the presence of adventitious agents, especially oncogenic viruses.

CRUCCELL

Crucell discovers and develops fully human biopharmaceuticals that utilize the immune system to combat disease. Crucell's proprietary technology platforms, MAbstract™, AdVac™ and PER.C6™, enable the discovery,

⁶ http://www.fda.gov/ohrtms/dockets/ac/01/briefing/3750b1_01.htm

⁷ Lewis *et al.*, "A defined-risks approach to the regulatory assessment of the use of neoplastic cells as substrates for viral vaccine manufacture", in *Evolving Scientific and Regulatory Perspectives on Cell Substrates for Vaccine Development*. Brown, Lewis, Peden, Krause (eds.) Develop. Biol. Stand.



development and production of novel antigens, Antibodies and Vaccines. Crucell offers its technology to pharmaceutical and biotechnology partners, and utilizes them to create Crucell's own product pipeline.

PER.C6™ is a human cell manufacturing platform, which has become the industry standard for production of recombinant adenoviral vectors. PER.C6™ has also proven to be a superior platform for the production of antibodies and vaccines.

Crucell has 19 licensees for its PER.C6™ technology, including Novartis, Pfizer, GSK, Aventis, Genzyme and Schering.

PER.C6™ in Crucell's Press Releases

PER.C6™ is a human cell platform for the development and manufacturing of bio-pharmaceutical products such as antibodies, proteins and vaccines. The superior yields and scalability of PER.C6, as well as the extensive history and safety documentation render PER.C6 the safe, cost effective and large-volume manufacturing platform that the pharmaceutical industry requires. Having launched the use of PER.C6 as a vaccine platform through an exclusive licensing agreement with Merck & Co. for their HIV vaccine, Crucell aims to expand its PER.C6 business in the field of vaccines. The current agreement with Rhein Biotech endorses this strategy.



CLAIMS

1. A method for producing competent gene products in human cells, said method comprising the following steps :

Providing a DNA construct in which a gene encoding a protein of interest is operably linked to a modified heat-inducible promoter,

Introducing said DNA construct into a human cell line, either by transformation or by transfection to form transformed or transfected host cell lines,

Subjecting said transformed or transfected cell lines to a transient increase in temperature and permitting the translation to protein to occur after the temperature has been returned to normal growth temperatures of the said host cells, whereby the production of said protein of interest occurs

2. The method of claim one in which the modified heat inducible promoter is the Hi-Hot promoter.

3. The method of claim one where the human cell line is a competent human hepatocyte cell line.

4. The method of claim 3 where the gene expressed encodes a therapeutic protein.

5. The method of claim 3 where the gene expressed includes therapeutic genes such as interferons, interleukins, blood clotting factors, insulins, growth hormone, urokinase, EPO, TPA, FSH, somatostatin, antibodies, DNAase, myoglobin, pro- and anti-angiogenesis factors and proteins of veterinary interest.

6. The method of claim 3 where the gene expressed is a natural liver protein.



ABSTRACT

A method for producing competent gene products in human cells, said method comprising the following steps :

Providing a DNA construct in which a gene encoding a protein of interest is operably linked to a modified heat-inducible promoter,

Introducing said DNA construct into a human cell line, either by transformation or by transfection to form transformed or transfected host cell lines,

Subjecting said transformed or transfected cell lines to a transient increase in temperature and permitting the translation to protein to occur after the temperature has been returned to normal growth temperatures of the said host cells, whereby the production of said protein of interest occurs